Cytotec[®]

misoprostol tablets

Cytotec

misoprostol tablets

Cytotec

effect, or both.

attained.

secretion.

and bleeding.

of the studies

misoprostol tablets

to tell whether the ability of misoprostol to

reduce the risk of gastric ulcer is the result of

its antisecretory effect, its mucosal protective

In vitro studies on canine parietal cells using

tritiated misoprostol acid as the ligand have led

to the identification and characterization of

specific prostaglandin receptors. Receptor

binding is saturable, reversible, and stereo-

specific. The sites have a high affinity for miso

prostol, for its acid metabolite, and for other E

type prostaglanding, but not for F or I prosta-

glandins and other unrelated compounds, such

as histamine or cimetidine. Receptor-site affin

rect index of antisecretory activity. It is likely

that these specific receptors allow misoprostol

taken with food to be effective topically,

despite the lower serum concentrations

Misoprostol produces a moderate decrease

in pepsin concentration during basal condi-

tions, but not during histamine stimulation. It

has no significant effect on fasting or post-

prandial gastrin nor on intrinsic factor output.

Effects on gastric acid secretion: Misoprostol,

over the range of 50-200 mcg, inhibits basal

and nocturnal gastric acid secretion, and acid

secretion in response to a variety of stimuli

including meals, histamine, pentagastrin, and coffee. Activity is apparent 30 minutes after

oral administration and persists for at least 3

hours. In general, the effects of 50 mcg were

modest and shorter lived, and only the 200-

mcg dose had substantial effects on nocturnal

secretion or on histamine and meal-stimulated

Uterine effects: Cytotec has been shown to

produce uterine contractions that may endan-

Other pharmacologic effects: Cytotec does not

produce clinically significant effects on serum

levels of prolactin, gonadotropins, thyroid-

stimulating hormone, growth hormone, thy-

(somatostatin, gastrin, vasoactive intestinal

polypeptide, and motilin), creatinine, or uric

acid. Gastric emptying, immunologic compe-

or the cardiovascular system are not

tence, platelet aggregation, pulmonary func-

modified by recommended doses of Cytotec.

Clinical studies: In a series of small short-term

(about 1 week) placebo-controlled studies in

healthy human volunteers, doses of miso-

prostol were evaluated for their ability to

reduce the risk of NSAID-induced mucosal

injury. Studies of 200 mcg g.i.d. of misoprostol

with tolmetin and naproxen, and of 100 and

200 mcg q.i.d. with ibuprofen, all showed

reduction of the rate of significant endoscopic

njury from about 70-75% on placebo to

10-30% on misoprostol. Doses of 25-200 mcg

q.i.d. reduced aspirin-induced mucosal injury

Reducing the risk of gastric ulcers caused by

(NSAIDs): Two 12-week, randomized, double

blind trials in osteoarthritic patients who had

gastrointestinal symptoms but no ulcer on

endoscopy while taking an NSAID compared

the ability of 200 mcg of Cytotec, 100 mcg of

Cytotec, and placebo to reduce the risk of

gastric ulcer (GU) formation. Patients were

approximately equally divided between ibupro-

fen, piroxicam, and naproxen, and continued

this treatment throughout the 12 weeks. The

200-mcg dose caused a marked, statistically

significant reduction in gastric ulcers in both

studies. The lower dose was somewhat less

effective, with a significant result in only one

nonsteroidal anti-inflammatory drugs

roxine, cortisol, gastrointestinal hormo

ger pregnancy. (See boxed WARNINGS.)

ity for misoprostol correlates well with an indi

Cytotec

misoprostol tablets

Therapy 4 weeks Study No. 1 Cytotec 200 mcg 1 (1.4) q.i.d. (n=74) Cytotec 100 mcg 3 (3.9) q.i.d. (n=77) Placebo (n=76) 11(14.5 Study No. 2 Cytotec 200 mcg 1 (1.5) q.i.d. (n=65) Cytotec 100 mcg 2 (3.0) q.i.d. (n=66) Placebo (n=62) 6 (9.7) Studies No. 1 & No. 2**

Cytotec 200 mcg 2 (1.4) a.i.d. (n=139) Cytotec 100 mcg 5 (3.5) q.i.d. (n=143) Placebo (n=138) 17 (12.3

* Statistically significantly different from placebo at the 5% level. *Combined data from Study No. 1 and Study No. 2.

In these trials there were no significant differences between Cytotec and placebo in relief of day or night abdominal pain. No effect of Cytotec in reducing the risk of duodenal ulcers was demonstrated, but relatively few duodenal lesions were seen.

In another clinical trial, 239 patients receiving aspirin 650-1300 mg q.i.d. for rheumatoid arthritis who had endoscopic evidence of duodenal and/or gastric inflammation were ran domized to misoprostol 200 mcg q.i.d. or placebo for 8 weeks while continuing to receive aspirin. The study evaluated the possible interference of Cytotec on the efficacy of aspirin in these patients with rheumatoid arthritis by analyzing joint tenderness, joint swelling, physician's clinical assessment, patient's assessment, change in ARA classification, change in handgrip strength, change in duration of morning stiffness, patient's assessment of pain at rest, movement, interference with daily activity, and ESR. Cytotec did not interfere with the efficacy of aspirin in these patients with rheumatoid arthritis.

INDICATIONS AND USAGE

Cytotec (misoprostol) is indicated for reducing the risk of NSAID (nonsteroidal anti-inflamr tory drugs, including aspirin)-induced gastric ulcers in patients at high risk of complica tions from gastric ulcer, eg, the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Cytotec has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Cytotec should be taken for the duration of NSAID therapy. Cytotec has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use

See boxed WARNINGS. Cytotec should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs

(NSAIDs). Cytotec should not be taken by anyone with a history of allergy to prostaglandir

WARNINGS See boxed WARNINGS.

WARNINGS

CYTOTEC (MISOPROSTOL) ADMINISTRA-TION TO WOMEN WHO ARE PREGNANT CAN CAUSE ABORTION, PREMATURE BIRTH OR BIRTH DEFECTS LITERINE RUPTURE HAS BEEN REPORTED WHEN CYTOTEC WAS ADMINISTERED IN PREG-NANT WOMEN TO INDUCE LABOR OR TO INDUCE ABORTION BEYOND THE EIGHTH WEEK OF PREGNANCY (see also PRECAU TIONS and LABOR AND DELIVERY) CYTOTEC SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS)

PATIENTS MUST BE ADVISED OF THE ABORTIFACIENT PROPERTY AND WARNED NOT TO GIVE THE DRUG TO OTHERS.

Cytotec should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric ulceration. In such patients, Cytotec may be prescribed if the patient


 has had a negative serum pregnancy test within 2 weeks prior to beginning therapy is capable of complying with effective contraceptive measures.

has received both oral and written warn ings of the hazards of misoprostol, the risk f possible contraception failure, and the danger to other women of childbearing potential should the drug be taken by mistake.

will begin Cytotec only on the second or third day of the next normal menstrual period.

DESCRIPTION Cytotec oral tablets contain either 100 mcg or 200 mcg of misoprostol, a synthetic prosta

Misoprostol contains approximately equal amounts of the two diastereomers presented below with their enantiomers indicated by (\pm)



M.W. = 382.5 C22H38O5 (±) methyl 11α,16-dihydroxy-16-methyl-9oxoprost-13E-en-1-oate

Misoprostol is a water-soluble, viscous liquid. Inactive ingredients of tablets are hydroge nated castor oil, hypromellose, microcrystalline cellulose, and sodium starch glycolate.

chain undergoes beta oxidation and the beta side chain undergoes omega oxidation followed by reduction of the ketone to give prostaglandin F analogs. n normal volunteers, Cytotec (misoprostol) is rapidly absorbed after oral administration with

CLINICAL PHARMACOLOGY

Pharmacokinetics: Misoprostol is extensively

absorbed, and undergoes rapid de-esterifica-

tion to its free acid, which is responsible for its

clinical activity and, unlike the parent com pound, is detectable in plasma. The alpha side

a T_{max} of misoprostol acid of 12 ± 3 minutes and a terminal half-life of 20-40 minutes There is high variability of plasma levels of misoprostol acid between and within studies but mean values after single doses show a

linear relationship with dose over the range of 200-400 mcg. No accumulation of misoprostol acid was noted in multiple dose studies; plasma steady state was achieved within two davs. Maximum plasma concentrations of miso-

prostol acid are diminished when the dose is taken with food and total availability of misoprostol acid is reduced by use of concomitan antacid. Clinical trials were conducted with concomitant antacid, however, so this effect does not appear to be clinically important.

Mean ± SD	C _{max} (pg/ml)	AUC(0-4) (pg·hr/ml)	T _{max} (min)
Fasting	811 ± 317	417 ± 135	14 ± 8
With Antacid	689 ± 315	$349 \pm 108^*$	20 ± 14
With High Fat Breakfast	303 ± 176*	373 ± 111	64 ± 79*

Comparisons with fasting results statistically significant, p<0.05

After oral administration of radiolabeled misoprostol, about 80% of detected radioactivity appears in urine. Pharmacokinetic studies in patients with varying degrees of renal impairment showed an approximate doubling of $T_{1/2}$, ax, and AUC compared to normals, but no clear correlation between the degree of impai ment and AUC. In subjects over 64 years of age, the AUC for misoprostol acid is increased. No routine dosage adjustment is recommended in older patients or patients with renal impairment, but dosage may need to be reduced if the usual dose is not tolerated. Cytotec does not affect the hepatic mixed

function oxidase (cytochrome P-450) enzyme systems in animals. Drug interaction studies between misopros

tol and several nonsteroidal anti-inflammatory drugs showed no effect on the kinetics of ibuprofen or diclofenac, and a 20% decrease in aspirin AUC, not thought to be clinically significant.

Pharmacokinetic studies also showed a lack of drug interaction with antipyrine and propranolol when these drugs were given with misoprostol. Misoprostol given for 1 week had no effect on the steady state pharmacokinetics of diazepam when the two drugs were administered 2 hours apart.

The serum protein binding of misoprostol acid is less than 90% and is concentrationindependent in the therapeutic range.

Pharmacodynamics: Misoprostol has both antisecretory (inhibiting gastric acid secretion) and (in animals) mucosal protective properties NSAIDs inhibit prostaglandin synthesis, and a deficiency of prostaglandins within the gastric mucosa may lead to diminishing bicarbonate and mucus secretion and may contribute to the ucosal damage caused by these agents. Misoprostol can increase bicarbonate and mucus production, but in man this has been shown at doses 200 mcg and above that are also antisecretory. It is therefore not possible



COMPOSITION ORDER # 19421	PRODUCT CYTOTEC			COPY CODE # 818 931 002
CCS #	NDC #	SL026 Rev. 6	Outs	sert
BOTTLE #	size 16 x 11"	FOLDED SIZE 2 x 1.375"	DRAWING	
ADDITIONAL INFORMATION Pharmacode 441		P04011-2	^{date} 02/24/03	TYPESET BY DHUFF





P04011-2

Cytotec[®] misoprostol tablets

818 931 002

glandin \tilde{E}_1 analog.

Cytotec

misoprostol tablets

PRECAUTIONS

Caution should be employed when adminis-tering Cytotec (misoprostol) to patients with pre-existing cardiovascular disease.

Information for patients: Women of childbear ing potential using Cytotec to decrease the risk of NSAID-induced ulcers should be told that they must not be pregnant when Cytotec therapy is initiated, and that they must use an effective contraception method while taking Cytotec

See boxed WARNINGS.

Cytotec is intended for administration along with nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, to decrease the chance of developing an NSAID-induced gastric ulcer.

Cytotec should be taken only according to the directions given by a physician. If the patient has questions about or prob-

lems with Cytotec, the physician should be contacted promptly.

THE PATIENT SHOULD NOT GIVE CYTOTEC TO ANYONE ELSE. Cytotec has been prescribed for the patient's specific condition, may not be the correct treatment for anothe person, and may be dangerous to the other person if she were to become pregnant.

The Cytotec package the patient receives from the pharmacist will include a leaflet containing patient information. The patient should read the leaflet before taking Cytotec and each time the prescription is renewed because the leaflet may have been revised.

Keep Cytotec out of the reach of children. SPECIAL NOTE FOR WOMEN: Cytotec may cause abortion (sometimes incomplete), premature labor, or birth defects if given to pregnant women

Cytotec is available only as a unit-of-use package that includes a leaflet containing patient information. See Patient Information at the end of this labeling

Drug interactions: See Clinical Pharmacology. Cytotec has not been shown to interfere with the beneficial effects of aspirin on signs and symptoms of rheumatoid arthritis. Cytotec does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. Cytotec has no clinically significant effect on the kinetics of diclofenac or ibuprofen.

Animal toxicology: A reversible increase in the number of normal surface gastric epithelial cells occurred in the dog, rat, and mouse. No such increase has been observed in humans administered Cytotec for up to 1 year.

An apparent response of the female mouse to Cytotec in long-term studies at 100 to 1000 times the human dose was hyperostosis, mainly of the medulla of sternebrae. Hyperostosis did not occur in long-term studies in the dog and rat and has not been seen in humans treated with Cytotec

Carcinogenesis, mutagenesis, impairment of fertility: There was no evidence of an effect of Cytotec on tumor occurrence or incidence in rats receiving daily doses up to 150 times the human dose for 24 months. Similarly, there was no effect of Cytotec on tumor occurrence or incidence in mice receiving daily doses up to 1000 times the human dose for 21 months. The mutagenic potential of Cytotec was tested in several in vitro assays, all of which were negative.

Misoprostol, when administered to breeding male and female rats at doses 6.25 times to 625 times the maximum recommended human therapeutic dose, produced dose-related preand post-implantation losses and a significant decrease in the number of live pups born at the highest dose. These findings suggest the possibility of a general adverse effect on fer tility in males and females.



Reduction of Risk of Gastric Ulcers Induced by Ibuprofen, Piroxicam, or Naproxen [No. of patients with ulcer(s) (%)]

erapy Duration					
;	8 weeks	12 weeks			
	0	0	1 (1.4)*		
	1 (1.3)	1 (1.3)	5 (6.5)*		
5)	4 (5.3)	4 (5.3)	19 (25.0)		
	1 (1.5)	0	2 (3.1)*		
	2 (3.0)	1 (1.5)	5 (7.6)		
	2 (3.2)	3 (4.8)	11 (17.7)		
6					
	1 (0.7)	0	3 (2.2)*		
	3 (2.1)	2 (1.4)	10 (7.0)*		
3)	6 (4.3)	7 (5.1)	30 (21.7)		

CONTRAINDICATIONS

Cytotec

misoprostol tablets

Pregnancy: Pregnancy Category X. Teratogenic effects: See boxed WARNINGS.

Congenital anomalies sometimes associated with fetal death have been reported subsequent to the unsuccessful use of misoprostol as an abortifacient, but the drug's teratogenic mechanism has not been demonstrated Several reports in the literature associate the use of misoprostol during the first trimester of pregnancy with skull defects, cranial nerve palsies, facial malformations, and limb defects Cytotec is not fetotoxic or teratogenic in rats and rabbits at doses 625 and 63 times the human dose, respectively.

Nonteratogenic effects: See boxed WARN-INGS. Cytotec may endanger pregnancy (may cause abortion) and thereby cause harm to the fetus when administered to a pregnant woman Cytotec may produce uterine contractions, uterine bleeding, and expulsion of the products of conception. Abortions caused by Cytotec may be incomplete. If a woman is or becomes pregnant while taking this drug to reduce the risk of NSAID-induced ulcers, the drug should be discontinued and the patient apprised of the potential hazard to the fetus.

Labor and delivery: Cytotec can induce or augment uterine contractions. Vaginal admin istration of Cytotec, outside of its approved indication, has been used as a cervical ripen ing agent, for the induction of labor and for treatment of serious postpartum hemorrhage in the presence of uterine atony. A major adverse effect of the obstetrical use of Cytotec is the hyperstimulation of the uterus which may progress to uterine tetany with marked impairment of uteroplacental blood flow, uterine rupture (requiring surgical repair, hysterectomy, and/or salpingo-oophorectomy), or amniotic fluid embolism. Pelvic pain, retained placenta, severe genital bleeding, shock, fetal bradycardia, and fetal and maternal death have been reported.

There may be an increased risk of uterine tachysystole, uterine rupture, meconium passage, meconium staining of amniotic fluid and Cesarean delivery due to uterine hyperstimulation with the use of higher doses of Cytotec, including the manufactured 100 mcg tablet. The risk of uterine rupture increases with advancing gestational ages and with prior uterine surgery, including Cesarean delivery. Grand multiparity also appears to be a risk factor for uterine rupture.

The effect of Cytotec on later growth, devel opment, and functional maturation of the child when Cytotec is used for cervical ripening or induction of labor have not been established. Information on Cytotec's effect on the need for forceps delivery or other intervention is unknown.

Nursing mothers: It is unlikely that Cytotec is excreted in human milk since it is rapidly metabolized throughout the body. However, i is not known if the active metabolite (misoprostol acid) is excreted in human milk. Therefore, Cytotec should not be administered to nursing mothers because the potential excre tion of misoprostol acid could cause significant diarrhea in nursing infants.

Pediatric use: Safety and effectiveness of Cytotec in pediatric patients have not been established.

ADVERSE REACTIONS

The following have been reported as adverse events in subjects receiving Cytotec:

Gastrointestinal: In subjects receiving Cytotec 400 or 800 mcg daily in clinical trials, the most frequent gastrointestinal adverse events were diarrhea and abdominal pain. The incidence of diarrhea at 800 mcg in controlled trials in patients on NSAIDs ranged from 14-40% and all studies (over 5,000 patients) averaged 13% Abdominal pain occurred in 13-20% of patients in NSAID trials and about 7% in all

Cytotec

misoprostol tablets

studies, but there was no consistent difference from placebo.

Diarrhea was dose related and usually developed early in the course of therapy (after 13 days), usually was self-limiting (often resolving after 8 days), but sometimes required discontinuation of Cytotec (2% of the patients). Rare instances of profound diarrhea leading to severe dehydration have been reported. Patients with an underlying condition such as inflammatory bowel disease, or those in whom dehydration, were it to occur, would be dan gerous, should be monitored carefully it Cytotec is prescribed. The incidence of diarrhea can be minimized by administering after meals and at bedtime, and by avoiding coadministration of Cytotec with magnesium-containing antacids.

Gvnecological: Women who received Cytoted during clinical trials reported the following gynecological disorders: spotting (0.7%), cramps (0.6%), hypermenorrhea (0.5%), menstrual disorder (0.3%) and dysmenorrhea (0.1%). Postmenopausal vaginal bleeding may be related to Cytotec administration. If it occurs, diagnostic workup should be undertaken to rule out gynecological pathology. (See boxed WARNINGS.)

Elderly: There were no significant differences in the safety profile of Cytotec in approximately 500 ulcer patients who were 65 years of age or older compared with younger patients

Additional adverse events which were reported are categorized as follows:

Incidence greater than 1%: In clinical trials, the following adverse reactions were reported by more than 1% of the subjects receiving Cytotec and may be causally related to the drug: nausea (3.2%), flatulence (2.9%), headache (2.4%), dyspepsia (2.0%), vomiting (1.3%), and constipation (1.1%). However, there were no significant differences between the incidences of these events for Cytotec and placebo.

(Causal) (relationship) (unknown:) The following adverse events were infrequently reported. Causal relationships between Cytotec and these events have not been established but cannot be excluded:

Body as a whole: aches/pains, asthenia, fatigue, fever, rigors, weight changes.

Skin: rash, dermatitis, alopecia, pallor, breast pain. Special senses: abnormal taste, abnormal

vision, conjunctivitis, deafness, tinnitus, earache.

Respiratory: upper respiratory tract infection, bronchitis, bronchospasm, dyspnea, pneumonia, epistaxis.

Cardiovascular: chest pain, edema, diaphoresis hypotension, hypertension, arrhythmia, phle bitis, increased cardiac enzymes, syncope, myocardial infarction (some fatal), throm boembolic events (e.g., pulmonary embolism, arterial thrombosis, and CVA).

Gastrointestinal: GI bleeding, GI inflammation, infection, rectal disorder, abnormal hepatobiliary function, gingivitis, reflux, dysphagia, amylase increase.

Hypersensitivity: anaphylaxis

Metabolic: glycosuria, gout, increased nitrogen, increased alkaline phosphatase Genitourinary: polyuria, dysuria, hematuria,

urinary tract infection. Nervous system/Psychiatric: anxiety, change

in appetite, depression, drowsiness, dizziness, thirst, impotence, loss of libido, sweating increase, neuropathy, neurosis, confusio Musculoskeletal: arthralgia, myalgia, muscle

cramps, stiffness, back pain. Blood/Coagulation: anemia, abnormal differ

ential, thrombocytopenia, purpura, ESR increased. OVERDOSAGE

The toxic dose of Cytotec in humans has not

Cytotec

misoprostol tablets

been determined. Cumulative total daily doses of 1600 mcg have been tolerated, with only symptoms of gastrointestinal discomfort being reported. In animals, the acute toxic effects are diarrhea, gastrointestinal lesions, focal cardiac necrosis, hepatic necrosis, renal tubular necrosis, testicular atrophy, respiratory difficulties, and depression of the central nervous system Clinical signs that may indicate an overdose are sedation, tremor, convulsions, dyspnea, abdominal pain, diarrhea, fever, palpitations hypotension, or bradycardia. Symptoms should be treated with supportive therapy. It is not known if misoprostol acid is dialyz-

able. However, because misoprostol is metab olized like a fatty acid, it is unlikely that dialysis would be appropriate treatment for over dosage

DOSAGE AND ADMINISTRATION

The recommended adult oral dose of Cytotec for reducing the risk of NSAID-induced gastric ulcers is 200 mcg four times daily with food. If this dose cannot be tolerated, a dose of 100 mcg can be used. (See Clinical Pharmacology: Clinical studies.) Cytotec should be taken for the duration of NSAID therapy as prescribed by the physician. Cytotec should be taken with a meal, and the last dose of the day should be at bedtime.

Renal impairment: Adjustment of the dosing schedule in renally impaired patients is not routinely needed, but dosage can be reduced if the 200-mcg dose is not tolerated. (See Clinical Pharmacology.)

HOW SUPPLIED

Cytotec 100-mcg tablets are white, round, with SEARLE debossed on one side and 1451 on the other side; supplied as: ND

NDC Number	<u>Size</u>
0025-1451-60	unit-of-use bottle of 60
0025-1451-20	unit-of-use bottle of 120
0025-1451-34	carton of 100 unit dose

Cytotec 200-mcg tablets are white, hexagonal, with SEARLE debossed above and 1461 debossed below the line on one side and a double stomach debossed on the other side; supplied as:

NDC Number

unit-of-use bottle of 60 0025-1461-60 unit-of-use bottle of 100 0025-1461-31 0025-1461-34 carton of 100 unit dose

Store at or below 25°C (77°F), in a dry area.

Read this leaflet before taking Cytotec® (miso-

renewed, because the leaflet may be changed. Cytotec (misoprostol) is being prescribed by your doctor to decrease the chance of getting stomach ulcers related to the arthritis/pair medication that you take.

therapy, stop taking Cytotec and contact your physician immediately. Remember that even if you are on a means of birth control it is still possible to become pregnant. Should this occur, stop taking Cytotec and contact your physician immediately.

818 931 002

Cytotec

misoprostol tablets

cramping, and/or nausea in some people. In most cases these problems develop during the first few weeks of therapy and stop after about a week. You can minimize possible diarrhea by making sure you take Cytotec with food

Because these side effects are usually mild to moderate and usually go away in a matter of days, most patients can continue to take Cytotec. If you have prolonged difficulty (more than 8 days), or if you have severe diarrhea, cramping and/or nausea, call your doctor. Take Cytotec only according to the direc-

tions given by your physician. Do not give Cytotec to anyone else. It has been prescribed for your specific condition, may not be the correct treatment for another person, and would be dangerous if the other person were pregnant.

This information sheet does not cover all possible side effects of Cvtotec. This patient nformation leaflet does not address the side effects of your arthritis/pain medication. See your doctor if you have questions. Keep out of reach of children.

 ${
m R}_{
m conly}$ Revised: February 2003

Searle & Co.

Caguas, PR

Manufactured for: G.D. Searle LLC A subsidiary of Pharmacia Corporation Chicago, IL 60680, USA

Pharmacia Limited Morpeth, England

PHARMACIA

Cytotec[®]

misoprostol tablets

P04011-2



COMPOSITION ORDER # 19421	PRODUCT			COPY CODE # 818 931 002
CCS #	NDC #	^{EDP #} SL026 Rev. 6	Ои	tsert
BOTTLE #	size 16 x 11"	FOLDED SIZE 2 x 1.375"	DRAWI	^{NG #} 026 Rev. 6
ADDITIONAL INFORMATION Pharmacode 441		P04011-2	DATE 02/24/03	TYPESET BY DHUFF

PATIENT INFORMATION

prostol) and each time your prescription is

Do not take Cytotec to reduce the risk of NSAID-induced ulcers if you are pregnant. (See boxed WARNINGS.) Cytotec can cause abortion (sometimes incomplete which could lead to dangerous bleeding and require hospitalization and surgery), premature birth, or birth defects. It is also important to avoid pregnancy while taking this medication and for at least one month or through one menstrual cycle after you stop taking it. Cytotec has been reported to cause the uterus to rupture (tear) when given after the eighth week of pregnancy. Rupture (tearing) of the uterus can result in severe bleeding, hysterectomy, and/or maternal or fetal death.

If you become pregnant during Cytotec

Cytotec may cause diarrhea, abdominal